Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 237-247 , May 2004

Economic burden of acute myeloid leukemia: a literature review

  • Alberto Redaelli

      Affiliations

    • Global Outcomes Research-Oncology, Pharmacia Corporation, Via Robert Koch 1.2, 20152 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-2-4838-2376; fax: +39-2-4838-2392
    • ,
  • Marc F Botteman

      Affiliations

    • HERQuLES, Bethesda, MD, USA
    • ,
  • Jennifer M Stephens

      Affiliations

    • HERQuLES, Bethesda, MD, USA
    • ,
  • Suzanne Brandt

      Affiliations

    • HERQuLES, Bethesda, MD, USA
    • ,
  • Chris L Pashos

      Affiliations

    • Health Economic Research and Quality of Life Evaluation Services (HERQuLES), Cambridge, MA, USA

References 

  1. Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int. J. Technol. Assess. Health. Care. 1994;10(4):683–694
  2. Stalfelt AM. Quality of life of patients with acute myeloid leukaemia. Leuk. Res. 1994;18(4):257–267
  3. Greenberg DB, Kornblith AB, Herndon JE, et al.  Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia Group B during the period 1971–1988: predictors for later psychologic distress. Cancer. 1997;80(10):1936–1944
  4. Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, et al.  Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J. Hematother. Stem Cell Res. 2001;10(1):187–192
  5. Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J. Intern. Med. 1994;236(4):401–409
  6. Menzin J, Lang K, Earle CC, et al.  The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med. 2002;162(14):1597–1603
  7. Stalfelt AM, Brodin H, Wadman B. Cost analysis of different phases of acute myeloid leukaemia. Leuk. Res. 1994;18(10):783–790
  8. Allan DS, Buckstein R, Imrie KR. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk. Lymphoma. 2001;42(3):339–346
  9. Girmenia C, Alimena G, Latagliata R, et al.  Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica. 1999;84(9):814–819
  10. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, et al.  Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant. 1995;15(4):605–610
  11. Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin. Ther. 1991;13(3):353–360
  12. Clavio M, Quintino S, Masoudi B, et al.  Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J. Exp. Clin. Cancer Res. 2001;20(2):165–173
  13. Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia. 1992;6(7):720–722
  14. Lobo PJ, Powles RL, Hanrahan A, Reynold DK. Acute myeloblastic leukaemia – a model for assessing value for money for new treatment programmes. BMJ. 1991;302(6772):323–326
  15. Uyl-de Groot CA, Lowenberg B, Vellenga E, et al.  Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br. J. Haematol. 1998;100(4):629–636
  16. Dufoir T, Saux MC, Terraza B, et al.  Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant. 1992;10(4):323–329
  17. Barr R, Furlong W, Henwood J, et al.  Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J. Clin. Oncol. 1996;14(5):1413–1420
  18. Bone marrow transplantation and peripheral blood stem cell transplantation, National Cancer Institute. Available from: www.meb.uni-bonn.de/cancernet/400110.html, accessed July 2002
  19. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J. Clin. Oncol. 2000;18(1):64–71
  20. Wagner ND, Quinones VW. Allogeneic peripheral blood stem cell transplantation: clinical overview and nursing implications. Oncol. Nurs. Forum. 1998;25(6):1049–1055
  21. Bennett C, Waters T, Stinson T, et al.  Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24(5):555–560
  22. Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C, et al.  Cost of allogeneic bone marrow transplantation in four diseases. Health Policy. 1989;12(3):309–317
  23. Beard ME, Inder AB, Allen JR, et al.  The costs and benefits of bone marrow transplantation. N. Z. Med. J. 1991;104(916):303–305
  24. van Agthoven M, Groot MT, Verdonck LF, et al.  Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 2002;30:243–251
  25. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute non-lymphocytic leukemia. N. Engl. J. Med. 1989;321(12):807–812
  26. Bennett CL, Hynes D, Godwin J, et al.  Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a southwest oncology group clinical trial. Cancer Invest. 2001;19(6):603–610
  27. Bennett CL, Stinson TJ, Tallman MS, et al.  Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55–70 years of age) with acute myelogenous leukemia. Eastern cooperative oncology group (E1490). Ann. Oncol. 1999;10(2):177–182
  28. Lu ZJ, Luo R, Erder H, et al.  Cost impact of Filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia. Proc. Am. Soc. Haematol. 1996;88: Abstract 209a
  29. Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann. Oncol. 1999;10(11):1355–1359

PII: S0305-7372(03)00205-6

doi: 10.1016/j.ctrv.2003.11.002

Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 237-247 , May 2004

Article Tools